PhRMA survey of pharmacogenomic and pharmacodynamic evaluations: What next

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 6, 2012, Pages 1035-1043

  Grecco, N ^a   Cohen, N ^a   Warner, A W ^b   Lopez Correa, C ^c   Truter, S L ^d   Snapir, A ^e   Piccoli, S P ^a   Wang, D ^a   Westelinck, A ^f   Hinman, L ^g   Franc, M A ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Génome Québec ^*  (Canada)

^d PFIZER INC   (United States)

^e ORION CORPORATION   (Finland)

^f GLAXOSMITHKLINE   (United States)

^g NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG INDUSTRY; DRUG RESEARCH; GENETIC ANALYSIS; HUMAN; LABORATORY; PHARMACODYNAMICS; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; STANDARD;

CLINICAL TRIALS AS TOPIC; DATA COLLECTION; DATA INTERPRETATION, STATISTICAL; DNA; DRUG INDUSTRY; EUROPE; INDIVIDUALIZED MEDICINE; INTERNET; LABORATORIES; LEGISLATION, DRUG; PHARMACOGENETICS; PHARMACOLOGY; QUALITY CONTROL; QUESTIONNAIRES; SPECIMEN HANDLING; UNITED STATES;

EID: 84861340994     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.334     Document Type: Review

References (20)

1. Williams, J.A. et al. PhRMA white paper on ADME pharmacogenomics. J. Clin. Pharmacol. 48, 849-889 (2008). (Pubitemid 351871964)
2. Lesko, L. US Food and Drug Administration Clinical Pharmacology Advisory Committee http://www.fda.gov/ohrms/dockets/ac/08/slides/2008-4351s1-02-FDA- corepresentation-files/frame.htm(2008).
3. European Medicines Agency. Guideline on the Use of Pharmacogenetic Methodologies in the Pharmacokinetic Evaluation of Medicinal Products: draft (EMA/CHMP/37646/2009)http://www.ema.europa.eu/docs/en-GB/document-library/ Scientific-guideline/2010/05/WC500090323.pdf (2010).
4. US Food and Drug Administration. Draft Guidance-Clinical Pharmacogenomics: Premarketing Evaluation in Early Phase Clinical Studies,http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM243702.pdf (2011).
5. Salloway, S. et al.; Bapineuzumab 201 Clinical Trial Investigators. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 73, 2061-2070 (2009).
6. US Food and Drug Administration. Cetuximab (Erbitux) and panitumumab (Vectibix),http://www.fda.gov/AboutFDA/CentersOffices/ OfficeofMedicalProductsandTobacco/CDER/ucm172905.htm (2009).
7. Gold, M. et al. Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement. Geriatr. Cogn. Disord. 30, 131-146 (2010).
8. Warner, A.W. et al. Challenges in obtaining adequate genetic sample sets in clinical trials: the perspective of the industry pharmacogenomics working group. Clin. Pharmacol. Ther. 89, 529-536 (2011).
9. Franc, M.A., Warner, A.W., Cohen, N., Shaw, P.M., Groenen, P. & Snapir, A. Current practices for DNA sample collection and storage in the pharmaceutical industry, and potential areas for harmonization: perspective of the I-PWG. Clin. Pharmacol. Ther. 89, 546-553 (2011).
10. US Food and Drug Administration. Guidance for Industry-Pharmacogenomic Data Submissions,http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ UCM126957.pdf (2005).
11. US Code of Federal Regulations 21 CFR Part 58 (Good Laboratory Practice for Nonclinical Laboratory Studies)http://www.access.gpo.gov/nara/cfr/waisidx- 09/21cfr58-09.html.
12. CLIA 42 CFR Part 493 Subpart E .http://wwwn.cdc.gov/clia/pdf/42cfr493- 2004.pdf.
13. Centers for Medicare and Medicaid Services. Clinical Laboratory Improvement Amendments (CLIA) of 1988,http://www.cms.gov/clia (1988).
14. European Medicines Agency. EMA/CHMP Guideline: Pharmacogenomics Briefing Meetings, http://www.ema.europa.eu/pdfs/human/pharmacogenetics/2022704en.pdf (2006).
15. Patterson, S.D. et al. Prospective-retrospective biomarker analysis for regulatory consideration: white paper from the industry pharmacogenomics working group. Pharmacogenomics 12, 939-951 (2011).
16. Kaitlin, K.I. Deconstructing the drug development process: the new face of innovation. Clin. Pharmacol. Ther. 87, 356-361 (2010).
17. International Drug Regulatory Affairs Compendium (IDRAC). FY 2010 Performance Report to the President and Congress for the Prescription Drug User Fee Act (120035) (2010).
18. Cohen, N. Pharmacogenomics and Personalized Medicine (Humana Press, Totowa, NJ, 2008).
19. Hamburg, M.A. & Collins, F.S. The path to personalized medicine. N. Engl. J. Med. 363, 301-304 (2010).
20. US Food and Drug Administration Table of Pharmacogenomic Biomarkers in Drug Labels,http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/ Pharmacogenetics/ucm083378.htm .